SCHEMBL143039

SCHEMBL143039

COc1ccc(-c2cc(C(=O)O)c(N)c(-c3ccc(OC)cc3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.57
MAPT P10636 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
LMNA P02545 3/20 0.54
NPC1 O15118 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
RAB9A P51151 2/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
ATM Q13315 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
PLA2G2A P14555 3/20 0.53
MCL1 Q07820 2/20 0.50
DYRK1A Q13627 1/20 0.50
CASP1 P29466 1/20 0.49
ALPL P05186 1/20 0.49
CA9 Q16790 1/20 0.49
CHEK1 O14757 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL140353 0.89 PLA2G2A (0.64) KDM4EMAPTSMN1; SMN2LMNANPC1
SCHEMBL110884 0.84 PLA2G2A (0.59) KDM4EMAPTALDH1A1PLA2G2ATP53
SCHEMBL110395 0.80 PLA2G2A (0.69) KDM4ESMN1; SMN2LMNANPC1ALDH1A1
SCHEMBL15976429 0.80 PLA2G2A (0.57) KDM4EMAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL178690 0.79 DYRK1A (0.55) KDM4EMAPTSMN1; SMN2LMNANPC1
SCHEMBL108830 0.78 PLA2G2A (0.55) KDM4EMAPTSMN1; SMN2LMNANPC1
SCHEMBL141016 0.78 PLA2G2A (0.55) KDM4EMAPTSMN1; SMN2LMNANPC1
SCHEMBL110393 0.78 DHODH (0.52) KDM4EMAPTALDH1A1NPSR1PLA2G2A
SCHEMBL116026 0.77 KDM4E (0.85) KDM4EMAPTSMN1; SMN2LMNANPC1
SCHEMBL5532004 0.75 KDM4E (0.69) KDM4EMAPTSMN1; SMN2LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 KDM4E 928/4885MAPT 4508/4885SMN1; SMN2 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.